Sort   by:  
 Page size 
TranscriptomicsAssessment of MEK-ERK pathway targeting by BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias [U266 human myeloma cell line]
Multiple myeloma (MM) is a malignant disorder characterized by the clonal proliferation of plasma cells (PCs) in the bone marrow (BM). The genetic background and clinical course of the disease are largely heterogeneous, and MM pathophysiology ranges from the premalignant condition of monoclonal gamm...
ORGANISM(S): Homo sapiens 
2015-07-01 | E-GEOD-66292 | biostudies-arrayexpress
TranscriptomicsDynamics of intercellular and exosomal miRNAs in hypoxia-resistant U266 cells
In multiple myeloma (MM), abnormal plasma cells interact with bone marrow (BM) stromal cells and vascular cells among others. A part of the BM milieu is considered highly hypoxic, and myeloma cells in situ may be influenced by circumstances other than normoxia in vitro. Hence, we attempted to confir...
ORGANISM(S): Homo sapiens 
2014-10-15 | E-GEOD-48910 | biostudies-arrayexpress
GenomicsExpression data from U266 MM cells untreated or treated with trabectedn
Expression data from U266 MM cells untreated or treated with trabectedn
PRJNA526059 | ENA
TranscriptomicsTranscription profiling of human U266, MM.1s, KMS11, 8226/S multiple myeloma cell lines treated with arsenic
We used microarrays to examine changes in gene expression in multiple myeloma cell lines following treatment with arsenic trioxide and darinaparsin Experiment Overall Design: Four multiple myeloma cell lines (U266, MM.1s, KMS11, 8226/S) were treated with either arsenic trioxide (ATO) for 6, 24, or 4...
ORGANISM(S): Homo sapiens 
2009-02-01 | E-GEOD-14519 | biostudies-arrayexpress
TranscriptomicsDynamics of intercellular and exosomal miRNAs in hypoxia-resistant U266 cells
In multiple myeloma (MM), abnormal plasma cells interact with bone marrow (BM) stromal cells and vascular cells among others. A part of the BM milieu is considered highly hypoxic, and myeloma cells in situ may be influenced by circumstances other than normoxia in vitro. Hence, we attempted to confir...
ORGANISM(S): Homo sapiens 
2014-10-15 | GSE48910 | GEO
GenomicsRNA sequencing of MM.1S and U266 cell lines after IT848 treatment
RNA sequencing of MM.1S and U266 cell lines after IT848 treatment
PRJNA824427 | ENA
UnknownAntimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Not available
S-EPMC4969056 | biostudies-literature
GenomicsGenomic profiling of HL60 and U266 blood cancer cell lines
Genomic profiling of HL60 and U266 blood cancer cell lines with (P as positive) or without (N as negative) CD34 cells using Agilent-014950 Human Genome CGH Microarray 4x44K.
ORGANISM(S): Homo sapiens 
2011-05-20 | GSE21923 | GEO
UnknownBaicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.
Not available
S-EPMC5958785 | biostudies-literature
TranscriptomicsRNAseq to investigate transcriptional changes in human MM cell lines due to panobinostat, 5-Azacytidine, panobinostat+5-Azacytidine or n-methyl-2-pyrroldine (NMP) treatments.
Purpose: We applied RNA sequencing technology for high-throughput analysis of transcriptional changes within human MM cell lines JJN3 and U266 due to individual and combination drug treatment. Methods: JJN3 and U266 cells were treated with pan-HDACi panbobinostat, DNMTi 5-Azacytidine, panobinostat+5...
ORGANISM(S): Homo sapiens 
2014-04-09 | E-GEOD-56623 | biostudies-arrayexpress
Sort   by:  
 Page size